Medicenna Therapeutics Corp. (MDNA) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Medicenna had cash, cash equivalents, and marketable securities of...
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief...
Medicenna Therapeutics Corp. (MDNA), a clinical-stage immunotherapy company, announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer (“CBO”), as part...
Medicenna Therapeutics Corp.(MDNA), a clinical-stage immunotherapy company, today announced a clinical update on the monotherapy dose escalation portion of the first-in-human,...
Medicenna Therapeutics Corp. (MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No. 11,680,090, titled "Interleukin-2 Fusion Proteins and...
Medicenna Therapeutics Corp. (MDNA), a clinical stage immuno-oncology company, today announced that on April 25, 2023 it received a notice (the “Extension Notice”) from the Nasdaq...
Medicenna Therapeutics Corp. (MDNA), a clinical stage immunotherapy company, today announced updated data from its Phase 1/2 ABILITY study of MDNA11, a next-generation IL-2 with...